The therapeutic effects of intravitreal Ranibizumab injection (IVR) and the efficacy of laser photocoagulation for the treatment of retinopathy of prematurity (ROP) are compared. The screening criteria for ROP were infants born with less than 32 weeks gestational period and/or weighed less than 1500 grams or unstable clinical course. After ethical approval from the Institutional Review Board, this retrospective study was conducted. The study considered 1315 infants and an observation was made that 36/42 (85.7%) eyes showed regression of ROP in the IVR group whereas 27/27 (100%) eyes that were treated with laser therapy showed regression of ROP (p=0.09). A considerable discrepancy in habituation of ROP in both groups with 12 eyes (28.6%) has been noted which is showing recurrence of ROP in the IVR group compared to 1 eye (3.7%) in the Laser group (P=0.01. In terms of anisometropia and refractive error, both groups made no notable difference. Squint was found remarkably higher in the laser group (29.6%) than in the IVR group (4.8%) (P=0.01). It was found that treating ROP eyes with laser treatment leads to greater improvement in infants than when treated by IVR. Moreover, a significant recurrence of ROP was discovered after IVR treatment in comparison with the laser treatment.
1. Blencowe H, Moxon SA, Gilbert C. Update on blindness due to retinopathy of prematurity globally and in India. Indian Pediatr. 2016;53:S89-92.
2. Gilbert C, Malik AN, Nahar N, Das SK, Visser L, Sitati S, et al. Epidemiology of ROP update–Africa is the new frontier. Semin Perinatol. 2019;43(6):317-22.
3. Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551-9.
4. Lyons CJ, Lambert SR. Taylor and Hoyt's Pediatric Ophthalmology and Strabismus E-Book. Elsevier Health Sciences; 2016.
5. Eldweik L, Mantagos IS. Role of VEGF inhibition in the treatment of retinopathy of prematurity. Semin Ophthalmol. 2016;31(1-2):163-8.
6. Hård AL, Smith LE, Hellström A. Nutrition, insulin-like growth factor-1 and retinopathy of prematurity. Semin Fetal Neonatal Med. 2013;18(3):136-42.
7. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2006 Feb;117(2):572-6. doi: 10.1542/peds.2005-2749. Erratum in: Pediatrics. 2006 Sep;118(3):1324. PMID: 16452383.
8. Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG. Laser treatment for retinopathy of prematurity. Lasers Med Sci. 2013;28(2):683-92.
9. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367(26):2515-26.
10. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684-94.
11. Good WV. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-48.
12. Singh SR, Katoch D, Handa S, Kaur S, Moharana B, Dogra M, et al. Safety and efficacy of 532 nm frequency-doubled Nd-YAG green laser photocoagulation for treatment of retinopathy of prematurity. Indian J Ophthalmol. 2019;67(6):860-5.
13. Lira RP, Calheiros AB, Barbosa MM, Oliveira CV, Viana SL, Lima DC. Efficacy and safety of green laser photocoagulation for threshold retinopathy of prematurity. Arq Bras Oftalmol. 2008;71(1):49-51.
14. Conrady CD, Hartnett ME. The role of anti-vascular endothelial growth factor agents in the management of retinopathy of prematurity. US Ophthalmic Review, 2017;10(1):57-63
15. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-15.
16. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153(2):327-33.
17. Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina (Philadelphia, Pa.). 2017;37(4):710-7.
18. Baumal CR, Goldberg RA, Fein JG. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2015;46(4):432-8.
19. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991-9.
20. Löfqvist C, Hansen-Pupp I, Andersson E, Holm K, Smith LE, Ley D, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol. 2009;127(5):622-7.
21. Şahin A, Şahin M, Cingü AK, Çınar Y, Türkcü FM, Yüksel H, et al. Intravitreal bevacizumab monotherapy for retinopathy of prematurity. Pediatr Int. 2013;55(5):599-603.
22. Li SP, Wang YW, Qi SL, Zhang YP, Deng G, Ding WZ, et al. Analogous β-carboline alkaloids harmaline and harmine ameliorate scopolamine-induced cognition dysfunction by attenuating acetylcholinesterase activity, oxidative stress, and inflammation in mice. Front Pharmacol. 2018;9:346.
23. Carneiro AM, Costa R, Falcao MS, Barthelmes D, Mendonça LS, Fonseca SL, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age‐related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90(1):e25-30.
24. Menke MN, Framme C, Nelle M, Berger MR, Sturm V, Wolf S. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol. 2015;15:20.
25. Lyu J, Zhang Q, Chen C, Xu Y, Ji X, Zhao P. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study. BMC Ophthalmol. 2019;19(1):60.
26. Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42(3):462-9.
27. Castellanos MA, Schwartz S, García-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol. 2013;97(7):816-9.
28. Hoerster R, Muether P, Dahlke C, Mehler K, Oberthür A, Kirchhof B, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2012;91(1):e74-5.
29. Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35(4):675-80.
30. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina (Philadelphia, Pa.). 2017;37(10):1847-58.
31. Feng J, Qian J, Jiang Y, Zhao M, Liang J, Yin H, et al. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China. Ophthalmology. 2017;124(3):408-9.
32. Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology. 2017;124(8):1156-64.
33. Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132(11):1327-33.
34. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008-15.
35. Sukgen EA, Koçluk Y. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 2019;257(1):49-55.
36. FEBO PA, Naciye Kabatas MD, Serdar Beken MD, Aysegul Zenciroglu MD, Nurullah Okumus MD. Systemic steroid for exudative retinal detachment following laser photocoagulation for retinopathy of prematurity. Am J Med Sci. 2015;3(5):67-9.
37. Wang J, Ren X, Shen L, Yanni SE, Leffler JN, Birch EE. Development of refractive error in individual children with regressed retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2013;54(9):6018-24.
38. Gunay M, Celik G, Gunay BO, Aktas A, Karatekin G, Ovali F. Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol. 2015;78(5):300-4.
39. Stoica F, Ladariu C, Koos MJ, Stanciu A, Olariu G, Andreescu N, et al. Refractive and visual outcome after laser-treated retinopathy of prematurity in Western Romania. Maedica. 2016;11(2):122-9.
40. Al-Otaibi AG, Aldrees SS, Mousa AA. Long term visual outcomes in laser treated threshold retinopathy of prematurity in Central Saudi Arabia. Saudi J Ophthalmol. 2012;26(3):299-303.
41. Sahni J, Subhedar NV, Clark D. Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months. Br J Ophthalmol. 2005;89(2):154-9.
Copyright © 2023 - All Rights Reserved - Archives of Pharmacy Practice
Developed by Archives of Pharmacy Practice